Correlation of FISH and PRAME Immunohistochemistry in Ambiguous Superficial Cutaneous Melanocytic Proliferations

Nathan T Harvey1,2, Joanne Peverall3, Nathan Acott1

  • 1Department of Anatomical Pathology, PathWest Laboratory Medicine, Perth, Australia.

Insights

Immunohistochemistry for PRAME is not a sufficient surrogate for fluorescence in situ hybridization (FISH) in diagnosing challenging melanocytic neoplasms. While PRAME showed mild-to-moderate agreement with FISH results, it cannot replace this molecular technique.

Area of Science:

  • Dermatopathology
  • Oncology
  • Molecular Diagnostics

Background:

  • Preferentially expressed antigen in melanoma (PRAME) is a tumor marker for melanocytic neoplasms.
  • Fluorescence in situ hybridization (FISH) is a valuable but resource-intensive diagnostic tool for melanocytic lesions.
  • PRAME immunohistochemistry offers a potentially more accessible diagnostic alternative.

Purpose of the Study:

  • To evaluate if PRAME immunohistochemistry can substitute for FISH analysis in challenging superficial melanocytic proliferations.
  • To assess the concordance between PRAME immunostaining and FISH results in a selected cohort of cases.

Main Methods:

  • Retrospective analysis of 55 melanocytic proliferation cases previously subjected to FISH.
  • Blinded immunohistochemical staining for PRAME performed on these cases.
  • Interpretation of PRAME staining by a panel of at least three dermatopathologists.

Main Results:

  • PRAME immunostaining concordance with FISH cytogenetic interpretation was observed in 76% of cases (42/55).
  • The unweighted kappa value indicated mild-to-moderate agreement (0.42) between PRAME IHC and FISH.
  • A correlation exists, but concordance is insufficient for PRAME IHC to replace FISH.

Conclusions:

  • PRAME immunohistochemistry is not a reliable surrogate for FISH testing in diagnosing problematic melanocytic proliferations.
  • Accurate diagnosis requires integrating clinical, morphological, immunohistochemical, and molecular data.
  • Further validation is needed before PRAME IHC can be considered a standalone diagnostic tool for these challenging cases.